Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Chemicals industry as a whole closed the day down 0.2% versus the S&P 500, which was down 0.1%. Laggards within the Chemicals industry included

Metabolix

(

MBLX

), down 5.4%,

Ceres

(

CERE

), down 2.1%,

Penford

(

PENX

), down 2.1%,

BioAmber

(

BIOA

), down 2.6% and

Synthesis Energy Sys

(

SYMX

), down 5.8%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Penford

(

PENX

) is one of the companies that pushed the Chemicals industry lower today. Penford was down $0.24 (2.1%) to $10.95 on heavy volume. Throughout the day, 41,113 shares of Penford exchanged hands as compared to its average daily volume of 26,300 shares. The stock ranged in price between $10.83-$11.38 after having opened the day at $11.26 as compared to the previous trading day's close of $11.19.

Penford Corporation, together with its subsidiaries, develops, manufactures, and markets specialty natural-based ingredient systems for food and industrial applications primarily in the United States. Penford has a market cap of $145.1 million and is part of the basic materials sector. Shares are down 12.9% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Penford a buy, no analysts rate it a sell, and 1 rates it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates

Penford

as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins.

Highlights from TheStreet Ratings analysis on PENX go as follows:

  • The net income growth from the same quarter one year ago has significantly exceeded that of the Chemicals industry average, but is less than that of the S&P 500. The net income increased by 4.1% when compared to the same quarter one year prior, going from $1.19 million to $1.24 million.
  • Net operating cash flow has significantly increased by 92.12% to -$0.28 million when compared to the same quarter last year. In addition, PENFORD CORP has also vastly surpassed the industry average cash flow growth rate of 35.32%.
  • PENFORD CORP reported flat earnings per share in the most recent quarter. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, PENFORD CORP turned its bottom line around by earning $0.32 versus -$0.77 in the prior year. This year, the market expects an improvement in earnings ($0.55 versus $0.32).
  • The gross profit margin for PENFORD CORP is currently extremely low, coming in at 14.59%. Regardless of PENX's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, PENX's net profit margin of 1.16% is significantly lower than the industry average.
  • PENX has underperformed the S&P 500 Index, declining 9.27% from its price level of one year ago. Looking ahead, other than the push or pull of the broad market, we do not see anything in the company's numbers that may help reverse the decline experienced over the past 12 months. Despite the past decline, the stock is still selling for more than most others in its industry.

You can view the full analysis from the report here:

Penford Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Ceres

(

CERE

) was down $0.01 (2.1%) to $0.69 on light volume. Throughout the day, 234,355 shares of Ceres exchanged hands as compared to its average daily volume of 393,100 shares. The stock ranged in price between $0.66-$0.71 after having opened the day at $0.71 as compared to the previous trading day's close of $0.70.

Ceres, Inc., an agricultural biotechnology company, develops and sells energy crops to produce renewable bioenergy feedstocks in North America. Ceres has a market cap of $33.7 million and is part of the basic materials sector. Shares are down 49.3% year-to-date as of the close of trading on Friday. Currently there are 2 analysts who rate Ceres a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates

Ceres

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on CERE go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Oil, Gas & Consumable Fuels industry and the overall market, CERES INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • CERE's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 78.66%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • CERE, with its very weak revenue results, has greatly underperformed against the industry average of 3.2%. Since the same quarter one year prior, revenues plummeted by 51.7%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • CERES INC has improved earnings per share by 19.4% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CERES INC reported poor results of -$1.31 versus -$1.22 in the prior year. This year, the market expects an improvement in earnings (-$0.90 versus -$1.31).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the Oil, Gas & Consumable Fuels industry average, but is less than that of the S&P 500. The net income increased by 19.4% when compared to the same quarter one year prior, going from -$8.97 million to -$7.23 million.

You can view the full analysis from the report here:

Ceres Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Metabolix

(

MBLX

) was another company that pushed the Chemicals industry lower today. Metabolix was down $0.05 (5.4%) to $0.91 on light volume. Throughout the day, 54,611 shares of Metabolix exchanged hands as compared to its average daily volume of 77,800 shares. The stock ranged in price between $0.90-$0.96 after having opened the day at $0.96 as compared to the previous trading day's close of $0.96.

Metabolix, Inc., a bioscience company, focuses on delivering sustainable solutions to the plastics and chemicals industries. It produces a family of biopolymers found in nature called polyhydroxyalkanoates, which occur naturally in living organisms and are chemically similar to polyesters. Metabolix has a market cap of $33.0 million and is part of the basic materials sector. Shares are down 23.6% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Metabolix a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Metabolix

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on MBLX go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Chemicals industry. The net income has decreased by 20.6% when compared to the same quarter one year ago, dropping from -$6.76 million to -$8.15 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Chemicals industry and the overall market, METABOLIX INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has declined marginally to -$8.97 million or 5.49% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • Looking at the price performance of MBLX's shares over the past 12 months, there is not much good news to report: the stock is down 37.59%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • METABOLIX INC's earnings per share declined by 15.0% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past year. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, METABOLIX INC swung to a loss, reporting -$0.88 versus $0.10 in the prior year. This year, the market expects an improvement in earnings (-$0.84 versus -$0.88).

You can view the full analysis from the report here:

Metabolix Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.